lecture 10 Flashcards

diseases of white blood cells and lymph nodes - to be able to give examples of major diseases covered in the lecture involving WBCs and lymph nodes - to gain an understanding of the signs, molecular basis and treatments of major diseases involving white blood cells and lymph nodes

1
Q

What are the adult reference ranges for blood cells?

A
  • white cells (x10^3/µL) = 4.8-10.8
  • granulocytes (%) = 40-70
  • neutrophils (x10^3/µL) = 1.4-6.5
  • lymphocytes (x10^3/µL) = 1.2-3.4
  • monocytes (x10^3/µL) = 0.1-0.6
  • eosinophils (x10^3/µL) = 0-0.5
  • basophils (x10^3/µL) = 0-0.02
  • red cells (x10^3/µL) = 4.3-5, men; 3.5-5.0, women
  • platelets (x10^3/µL) = 150-450
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How are reference ranges used?

A
  • if someone lies outside the range it can indicate disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do blood cells develop?

A
  • from HSCs through well defined paths of differentiation, of which a number of the important transcription factors/chemokines are known
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Where is the ‘haematopoietic stem cell niche?

A
  • in the bone marrow

- endosteal part of bone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What cell types are found in the niche?

A
  • endothelial cells
  • nerve cells: can direct stem cell differentiation
  • osteoblasts: may have a role in signalling
  • stromal cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What organs are important for the development and maturation of WBCs?

A
  • bone marrow: where they arise
  • lymph nodes
  • thymus: almost exclusively T cells
  • spleen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are some of the major white blood cell types?

A
  • B lymphocyte: antibody secretion after detection of antigen and differentiation into plasma cells
  • CD4+ helper T lymphocyte: after presentation of antigen they release cytokines which stimulate activation of macrophages, inflammation and B lymphocytes
  • CD8+ cytotoxic T lymphocyte: kill infected body cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are all the names for neutrophils?

A
  • neutrophil
  • polymorphonuclear leukocyte, PMN, PML
  • “Leukocyte”
  • granulocyte, neutrophilic granulocyte
  • polymorph
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What does a neutrophil generally look like?

A
  • lobular nucleus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the functions of a neutrophil?

A
  • margination
  • rolling
  • adhesgion
  • transmigration (diapedesis)
  • chemotaxis
  • phagocytosis: recognition, engulfment, killing (digestion)
  • equilibrium with splenic pool
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is leukopenia?

A
  • the number of circulating white cells may be markedly decreased in a variety of disorders
  • an abnormally low white cell count (leukopenia) usually results from reduced numbers of neutrophils
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is neutropenia?

A
  • a reduction in the number of neutrophils in the blood, occurs in a wide variety of circumstances
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is agranulocytosis?

A
  • a clinically significant reduction in neutrophils – susceptibility to bacterial and fungal infections
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are reasons for inadequate production of neutrophils?

A
  • stem cell suppression e.g. aplastic anaemias
  • drugs especially chemo, many antibiotics
  • inherited defects in specific genes impairing granulocytic differentiation - Kostmann Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are reasons for increased destruction of neutrophils?

A
  • immune mediated
    – idiopathic, or consequence of immune disorder, e.g. SLE (system lupus erythematosus )
    – after “sensitisation” by drugs - antibiotics
  • splenic sequestration, spleen-blockage-enlargement - can be fatal in children
  • increased peripheral demand, as in overwhelming infections, especially fungal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is leukocytosis?

A

Increase in the number of white cells in the blood.

Reaction to a variety of inflammatory states.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the pathogenesis of leukocytosis influenced by?

A
  • size of the myeloid and lymphoid precursor and storage cell pools in the bone marrow, thymus, circulation and peripheral tissues
  • rate of release of cells from the storage pools into the circulation
  • the proportion of cells that are adherent to blood vessel walls at any time (the marginal pool)
  • the rate of extravasation of cells from the blood into tissues
18
Q

What is leukocytosis often accompanied by in sepsis or severe inflammatory disorders?

A
  • morphologic changes in the neutrophils

- e.g. toxic granulations, Döhle bodies, and cytoplasmic vacuoles

19
Q

What is lymphadenitis?

A

Acute nonspecific lymphadenitis - usually self limiting

  • very sore lymph nodes
  • caused by microbial drainage from infections of the teeth or tonsils
  • acute lymphadenitis in mesenteric lymph nodes draining acute appendicitis
  • systemic viral infections (particularly in children) and bacteremia often produce acute generalised lymphadenopathy
20
Q

What are lymphoid neoplasms?

A
  • include a diverse group of tumours of B-cell, T-cell, and NK-cell origin
  • in many instances the phenotype of the neoplastic cell closely resembles that of a particular stage of normal lymphocyte differentiation, a feature that is used in the diagnosis and classification of these disorders?
21
Q

What are myeloid neoplasms?

A
  • arise from early haematopoietic progenitors
    3 categories of myeloid neoplasia:
  • acute myeloid leukaemias (AML), in which immature progenitor cells accumulate in the bone marrow
  • myelodysplastic syndromes, which are associated with ineffective haematopoiesis and resultant peripheral blood cytopenias
  • chronic myeloproliferative leukemia (CML) - increased production of one or more terminally differentiated myeloid elements (e.g. granulocytes) usually leads to elevated peripheral blood counts
22
Q

What are the etiologic and pathogenetic factors in white cell neoplasia?

A
  • nonrandom chromosomal abnormalities, most commonly translocations, are present in the majority of white cell neoplasms
  • these translocations result in gene fusions generating abnormal oncogenic mRNAs and proteins
  • e.g. The philadelphia chromosome t(9;22) is present in approximately 3% of children with ALL and leads to production of a BCR-ABL1 fusion protein with tyrosine kinase activity
23
Q

Why are white cells so prone to translocation disorders?

A
  • because they’re dividing rapidly, increasing the statistical chance that something may happen
  • also perhaps genetically predisposed to not being able to check for errors properly
24
Q

What is the molecular pathogenesis of acute leukaemia?

A
  • acute leukaemia arise from complementary mutations that block differentiation at early stages of white cell development, enhance self-renewal, and increase growth and survival
  • e.g. BCR-ABL, breakpoint chromosomal region - Abelson kinase fusion gene; PML-RAR-alpha, promyelocyctic leukaemia-retinoic acid receptor alpha fusion; MLL, mixed-lineage leukaemia gene
  • BCR-ABL leads to increased growth of progenitor cells, tyrosine kinase mutation
  • PML-RAR-alpha blocks transcription factor mutations that lead to differentiation

MLL: fusion with FPG (abnormal function), or repeat of part of MLL gene producing a duplicate domain

25
Q

What is the molecular pathogenesis of acute leukaemia?

A

chronic immune stimulation

  • several environmental agents that cause localised chronic immune stimulation predispose to lymphoid neoplasia, which almost always arises within the inflamed tissue
  • H. pylori infection and gastric B-cell lymphomas
  • Gluten-sensitive enteropathy and intestinal T-cell lymphomas

Iatrogenic factors

  • radiation therapy and certain forms of chemotherapy used treat cancer increase the risk of subsequent myeloid and lymphoid neoplasms
  • stems from the mutagenic effects of ionising radiation and chemotherapeutic drugs on hematolymphoid progenitor cells

Smoking
- the incidence of AML is increased 1.3- to 2-fold in smokers, due to exposure to carcinogens, such as benzene, in tobacco smoke

26
Q

What are the three major lymphotropic viruses?

A
  • human t-cell leukaemia virus-1 (HTLV-1)
  • epstein-barr virus (EBV)
  • kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV-8)
27
Q

From which cells do lymphoid neoplasms normally arise?

A
  • the vast majority (85% - 90%) of lymphoid neoplasms are of B-cell origin, with most of the remainder being T-cell tumours
28
Q

What is leukaemia?

A
  • involve bone marrow and (usually, but not always) the peripheral blood
29
Q

What are lymphomas?

A

arise as discrete tissue ‘tumours’ - e.g. in lymph nodes

30
Q

What are the common clinical features of ALL?

A
  • abrupt stormy onset within days to a few weeks of the first symptoms
  • symptoms related to depression of marrow function, including fatigue due to anaemia; fever, reflecting infections secondary to neutropenia; and bleeding due to thrombocytopenia
  • mass effects caused by neoplastic infiltration (which are more common ALL), including bone pain resulting from marrow expansion; generalised lymphadenopathy, splenomegaly, a hepatomegaly; testicular enlargement; and in T-ALL, complications related to compression of large vessels and airways in the mediastinum
  • (not common)central nervous system manifestations such as headache, vomiting, and nerve palsies resulting from meningeal spread, all of which are also more common in ALL
31
Q

What is the prognosis for someone with ALL?

A
  • with aggressive chemotherapy about 95% of children with ALL obtain a complete remission, and 75% to 85% are cured
  • however ALL remains the leading cause of cancer deaths in children, and only 35% to 40% of adults are cured
32
Q

What is ALL?

A

Acute lymphoblastic leukaemia/lymphomas

  • composed of immature B (pre-B) or T (pre-T) cells, which are referred to as lymphoblasts
  • about 85% are B-ALLs, which typically manifest as childhood acute “leukaemias”
  • the less common T-ALLs tend to present in adolescent males and thymic “lymphomas”
33
Q

How do we diagnose ALL?

A
  • blood smear (morphology) - accumulation of ‘blasts

- expression of particular markers/known receptors - e.g. intracellular TdT, CDs (22, 19, 10)

34
Q

What are the molecular features of ALL?

A
  • approximately 90% of ALLs have numerical or structural chromosomal changes/mutations
  • with respect to gene mutations: single mutations are not sufficient to produce ‘ALL’
  • studies of identical twins with concordant B-ALL: same mutation but different ‘evolution’ over time ie. further mutations required
  • many of the chromosomal aberrations seen in ALL d ysregulate the expression and function of transcription factors that are required for normal B- and T-cell development
  • T-ALLs - NOTCH1 TF
  • B-ALLs - PAX5, E2A, TFs
35
Q

How can you detect the difference between AML and ALL via blood smear?

A

AML

  • more cytoplasm in blast cells
  • CD34, CD64, CD33, CD15

ALL

  • most taken up by nucleus
  • intracellular TdT, CDs (22, 19, 10)
36
Q

What is multiple myeloma?

A
  • causes 1% of all cancer deaths in Western countries
  • Its incidence is higher in men and people of African descent
  • It is chiefly a disease of the elderly, with a peak age of incidence 65 to 70 years
  • plasma cell neoplasm characterised by multifocal involvement of the skeleton
  • less common manifests in lymph nodes and/or skin
  • normal marrow cells are largely replaced by plasma cells, including forms with multiple nuclei, prominent nucleoli, and cytoplasmic droplets containing Ig
37
Q

What is the biochemical diagnosis of MM?

A
  • in 99% of patients, laboratory analyses reveal increased levels of Igs in the blood and/or light chains (Bence Jones proteins) in the urine
  • the most common monoclonal Ig (“M protein”) is IgG (~55% of patients), followed by IgA (~25% of cases)
  • myelomas expressing IgM, IgD, or IgE occur but are rare
  • you get a really thick band as opposed to a smear on gel electrophoresis
38
Q

What is the molecular and cellular pathogenesis of MM?

A
  • the Ig genes in myeloma cells always show evidence of somatic hypermutation
  • the cell of origin is considered to be a post-germinal centre B cell that homes to the bone marrow and has differentiated into a plasma cell
  • may originate in and be maintained by stem-like cells resembling small B lymphocytes via oncogenic signals generated by the “hedgehog” pathway for self-renewal
  • a key factor promoting the proliferation and survival of myeloma cells is IL-6 via autocrine and paracrine signalling from stromal cells
  • factors produced by neoplastic plasma cells mediate bone destruction, the major pathologic feature of multiple myeloma
  • myeloma-derived MIP1-alpha upregulates the expression of the receptor activator NF-kappaB ligand (RANKL) by bone marrow stromal cells, which in turn activates osteoclasts
  • further enhancing this effect is the Wnt-pathway mediated inhibition of osteoblasts
39
Q

What is the prognosis and treatment of MM?

A
  • prognosis is variable but generally poor
  • median survival is 4 - 6 years, and cures have yet to be achieved
  • patients with multiple bony lesions, if untreated, rarely survive for more than 6-12 months, whereas patients with “smouldering myeloma” may be asymptomatic for many years
  • translocations involving cyclin D1 are associated with a good outcome, whereas deletions of 13q, deletions of 17p, and the t(4;14) all require aggressive therapies
  • chemotherapy induces remission in 50% to 70% of patients
40
Q

What is Anaplastic Large-Cell Lymphoma?

A
  • defined by the presence of rearrangements in the anaplastic lymphoma kinase (ALK) gene
  • rearrangements break the anaplastic lymphoma kinase (ALK) locus and lead to the formation of chimeric genes encoding ALK fusion proteins, constitutively active tyrosine kinases that trigger a number of proliferation and survival signalling pathways, including the JAK/STAT pathway
  • the cure rate with chemotherapy is 75% to 80%
  • inhibitors of ALK are under development and offer an excellent opportunity for the development of a selective, targeted therapy
  • ALK-specific antigen vaccine